In Missouri, Monsanto Company reached a non-exclusive, multi-year global licensing agreement with Israel-based NRGene that allows NRGene’s genome analysis technology to enhance Monsanto’s ability to predict, compare and select the best genetic makeup from its vast data sets of genetic, genomic and trait information. The GenoMAGIC platform was developed by highly experienced algorithm designers, software engineers, plant breeders and plant geneticists and is used by seed companies and major academic and research institutions around the world.
With nearly half of Monsanto’s annual R&D investment focused on plant breeding, the use of leading genome analysis technologies like GenoMAGIC – along with the industry’s largest testing capability and scale and premier discovery technologies – are expected to increase current genetic gain.
Monsanto may expand its relationship with NRGene into a longer term commitment following an in-depth evaluation of the technology. The GenoMAGIC platform extends Monsanto’s capabilities for genome selection, trait discovery, and genome enhancement.